Background Soluble CD40 ligand (sCD40L) is a powerful marker of cardiovascular risk. Exercise is known to decrease cardiovascular risk, but the impact of ultra-endurance exercise on sCD40L responses ...

Eledon Pharmaceuticals, Inc. ( (ELDN) ) has released its Q3 earnings. Here is a breakdown of the information Eledon Pharmaceuticals, Inc.

In contrast, after adding 20 mg/kg of monoclonal antibody against CD40 ligand to the regimen on days 0 and 2, we observed four thromboembolic complications in nine recipients. These included two ...

Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline ...

CHATHAM, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical ...

In February, phase II trial data showed that frexalimab, an investigational second-generation CD40 ligand inhibitor, led to ...

Tegoprubart works against the CD40 ligand and that is to block the communication between cells from responding to one another. Thus, this in turn reduces T-cell, B-cell and cytokine activity to ...

Tonix's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting ...

The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad ...

At this time, I would like to welcome everyone to the Biogen third quarter 2024 earnings call and business update. [Operator ...

Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Announced positive ini ...